A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients

A. Testa, S. Prudente, D. Leonardis, B. Spoto, M. C. Sanguedolce, R. M. Parlongo, G. Tripepi, S. Rizza, F. Mallamaci, M. Federici, V. Trischitta, C. Zoccali

Research output: Contribution to journalArticle

Abstract

Introduction: The strongest genetic marker of uric acid levels, the rs734553 SNP in the GLUT9 urate transporter gene, predicts progression to kidney failure in CKD patients and associates with systolic BP and carotid intima media thickness in family-based studies. Methods: Since genes are transmitted randomly (Mendelian randomization) we used this gene polymorphism as an unconfounded research instrument to further explore the link between uric acid and cardiovascular disease (cardiovascular death, and non-fatal myocardial infarction and stroke) in a meta-analysis of three cohort studies formed by high risk patients (MAURO: 755 CKD patients; GHS: 353 type 2 diabetics and coronary artery disease and the TVAS: 119 patients with myocardial infarction). Results: In separate analyses of the three cohorts, the incidence rate of CV events was higher in patients with the rs734553 risk (T) allele (TT/GT) than in those without (GG patients) and the HR in TT/GT patients in the three cohorts (range 1.72-2.14) coherently signaled an excessive cardiovascular risk with no heterogeneity (I2 = 0.01). The meta-analytical estimate (total number of patients, n = 1227; total CV events, n = 222) of the HR for the combined end-point in TT/GT patients was twice higher (pooled HR: 2.04, 95% CI: 1.11-3.75, P = 0.02) than in GG homozygotes. Conclusions: The T allele of the rs734553 polymorphism in the GLUT9 gene predicts a doubling in the risk for incident cardiovascular events in patients at high cardiovascular risk. Findings in this study are compatible with the hypothesis of a causal role of hyperuricemia in cardiovascular disease in high risk conditions.

Original languageEnglish
Pages (from-to)1087-1094
Number of pages8
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume25
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Hyperuricemia
Genetic Markers
Meta-Analysis
Cohort Studies
Uric Acid
Genes
Cardiovascular Diseases
Alleles
Myocardial Infarction
Carotid Intima-Media Thickness
Homozygote
Random Allocation
Renal Insufficiency
Single Nucleotide Polymorphism
Coronary Artery Disease
Stroke

Keywords

  • Cardiovascular risk
  • Epidemiology
  • Polymorphism
  • Uric acid

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients. / Testa, A.; Prudente, S.; Leonardis, D.; Spoto, B.; Sanguedolce, M. C.; Parlongo, R. M.; Tripepi, G.; Rizza, S.; Mallamaci, F.; Federici, M.; Trischitta, V.; Zoccali, C.

In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 25, No. 12, 01.12.2015, p. 1087-1094.

Research output: Contribution to journalArticle

Testa, A, Prudente, S, Leonardis, D, Spoto, B, Sanguedolce, MC, Parlongo, RM, Tripepi, G, Rizza, S, Mallamaci, F, Federici, M, Trischitta, V & Zoccali, C 2015, 'A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients', Nutrition, Metabolism and Cardiovascular Diseases, vol. 25, no. 12, pp. 1087-1094. https://doi.org/10.1016/j.numecd.2015.08.004
Testa, A. ; Prudente, S. ; Leonardis, D. ; Spoto, B. ; Sanguedolce, M. C. ; Parlongo, R. M. ; Tripepi, G. ; Rizza, S. ; Mallamaci, F. ; Federici, M. ; Trischitta, V. ; Zoccali, C. / A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients. In: Nutrition, Metabolism and Cardiovascular Diseases. 2015 ; Vol. 25, No. 12. pp. 1087-1094.
@article{51f6f2147aa7488597b8b287b87b1504,
title = "A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients",
abstract = "Introduction: The strongest genetic marker of uric acid levels, the rs734553 SNP in the GLUT9 urate transporter gene, predicts progression to kidney failure in CKD patients and associates with systolic BP and carotid intima media thickness in family-based studies. Methods: Since genes are transmitted randomly (Mendelian randomization) we used this gene polymorphism as an unconfounded research instrument to further explore the link between uric acid and cardiovascular disease (cardiovascular death, and non-fatal myocardial infarction and stroke) in a meta-analysis of three cohort studies formed by high risk patients (MAURO: 755 CKD patients; GHS: 353 type 2 diabetics and coronary artery disease and the TVAS: 119 patients with myocardial infarction). Results: In separate analyses of the three cohorts, the incidence rate of CV events was higher in patients with the rs734553 risk (T) allele (TT/GT) than in those without (GG patients) and the HR in TT/GT patients in the three cohorts (range 1.72-2.14) coherently signaled an excessive cardiovascular risk with no heterogeneity (I2 = 0.01). The meta-analytical estimate (total number of patients, n = 1227; total CV events, n = 222) of the HR for the combined end-point in TT/GT patients was twice higher (pooled HR: 2.04, 95{\%} CI: 1.11-3.75, P = 0.02) than in GG homozygotes. Conclusions: The T allele of the rs734553 polymorphism in the GLUT9 gene predicts a doubling in the risk for incident cardiovascular events in patients at high cardiovascular risk. Findings in this study are compatible with the hypothesis of a causal role of hyperuricemia in cardiovascular disease in high risk conditions.",
keywords = "Cardiovascular risk, Epidemiology, Polymorphism, Uric acid",
author = "A. Testa and S. Prudente and D. Leonardis and B. Spoto and Sanguedolce, {M. C.} and Parlongo, {R. M.} and G. Tripepi and S. Rizza and F. Mallamaci and M. Federici and V. Trischitta and C. Zoccali",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.numecd.2015.08.004",
language = "English",
volume = "25",
pages = "1087--1094",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier B.V.",
number = "12",

}

TY - JOUR

T1 - A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients

AU - Testa, A.

AU - Prudente, S.

AU - Leonardis, D.

AU - Spoto, B.

AU - Sanguedolce, M. C.

AU - Parlongo, R. M.

AU - Tripepi, G.

AU - Rizza, S.

AU - Mallamaci, F.

AU - Federici, M.

AU - Trischitta, V.

AU - Zoccali, C.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Introduction: The strongest genetic marker of uric acid levels, the rs734553 SNP in the GLUT9 urate transporter gene, predicts progression to kidney failure in CKD patients and associates with systolic BP and carotid intima media thickness in family-based studies. Methods: Since genes are transmitted randomly (Mendelian randomization) we used this gene polymorphism as an unconfounded research instrument to further explore the link between uric acid and cardiovascular disease (cardiovascular death, and non-fatal myocardial infarction and stroke) in a meta-analysis of three cohort studies formed by high risk patients (MAURO: 755 CKD patients; GHS: 353 type 2 diabetics and coronary artery disease and the TVAS: 119 patients with myocardial infarction). Results: In separate analyses of the three cohorts, the incidence rate of CV events was higher in patients with the rs734553 risk (T) allele (TT/GT) than in those without (GG patients) and the HR in TT/GT patients in the three cohorts (range 1.72-2.14) coherently signaled an excessive cardiovascular risk with no heterogeneity (I2 = 0.01). The meta-analytical estimate (total number of patients, n = 1227; total CV events, n = 222) of the HR for the combined end-point in TT/GT patients was twice higher (pooled HR: 2.04, 95% CI: 1.11-3.75, P = 0.02) than in GG homozygotes. Conclusions: The T allele of the rs734553 polymorphism in the GLUT9 gene predicts a doubling in the risk for incident cardiovascular events in patients at high cardiovascular risk. Findings in this study are compatible with the hypothesis of a causal role of hyperuricemia in cardiovascular disease in high risk conditions.

AB - Introduction: The strongest genetic marker of uric acid levels, the rs734553 SNP in the GLUT9 urate transporter gene, predicts progression to kidney failure in CKD patients and associates with systolic BP and carotid intima media thickness in family-based studies. Methods: Since genes are transmitted randomly (Mendelian randomization) we used this gene polymorphism as an unconfounded research instrument to further explore the link between uric acid and cardiovascular disease (cardiovascular death, and non-fatal myocardial infarction and stroke) in a meta-analysis of three cohort studies formed by high risk patients (MAURO: 755 CKD patients; GHS: 353 type 2 diabetics and coronary artery disease and the TVAS: 119 patients with myocardial infarction). Results: In separate analyses of the three cohorts, the incidence rate of CV events was higher in patients with the rs734553 risk (T) allele (TT/GT) than in those without (GG patients) and the HR in TT/GT patients in the three cohorts (range 1.72-2.14) coherently signaled an excessive cardiovascular risk with no heterogeneity (I2 = 0.01). The meta-analytical estimate (total number of patients, n = 1227; total CV events, n = 222) of the HR for the combined end-point in TT/GT patients was twice higher (pooled HR: 2.04, 95% CI: 1.11-3.75, P = 0.02) than in GG homozygotes. Conclusions: The T allele of the rs734553 polymorphism in the GLUT9 gene predicts a doubling in the risk for incident cardiovascular events in patients at high cardiovascular risk. Findings in this study are compatible with the hypothesis of a causal role of hyperuricemia in cardiovascular disease in high risk conditions.

KW - Cardiovascular risk

KW - Epidemiology

KW - Polymorphism

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=84952874080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952874080&partnerID=8YFLogxK

U2 - 10.1016/j.numecd.2015.08.004

DO - 10.1016/j.numecd.2015.08.004

M3 - Article

C2 - 26607700

AN - SCOPUS:84952874080

VL - 25

SP - 1087

EP - 1094

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 12

ER -